MedTrace Logo

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

NCT01770483 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2013-09-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response by more than 80%.Considering that the study is being conducted in a third world country like Pakistan, the standard treatment of hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in efficacy to peginterferon and also cost effective.

Conditions

  • Hepatitis C, Chronic
  • DIABETES MELLITUS Type 2

Interventions

DRUG

nitazoxanide

nitazoxanide 500mg twice daily

DRUG

conventional interferon alfa

Inj interferon 3 Million International Units thrice weekly

DRUG

Ribavirin

ribazole

Sponsors & Collaborators

  • Getz Pharma

    collaborator INDUSTRY

  • Services Institute of Medical Sciences, Pakistan

    lead OTHER_GOV

Principal Investigators

  • FAISAL MASUD, FRCP · Principal SIMS/Services hospital lahore

  • AMENA MIRZA, MRCP,FCPS · Senior registrar ,Services hospital lahore/SIMS

  • Madiha Fida, MBBS · House Officer Services Hospital Lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01770483 on ClinicalTrials.gov